Chad Robins, CEO of Adaptive Biotechnologies.
Anjali Sundaram | CNBC
Ark Invest analyst Simon Barnett on Monday explained the company’s approach to what it calls the genomic revolution, splitting up two of its favorite interests: Adaptive Biotechnologies and Invitae.
In an interview on CNBC’s “Closing Bell,” Barnett said Cathie Wood-led Ark Invest sees great potential for investors in the molecular biology arm known as genomics, calling it “one of the most transformative investment opportunities of the century. . “
Ark’s family of funds includes the Genomic Revolution ETF (ARKG), which aims to provide investors with exposure to areas such as DNA sequencing technology and molecular diagnostics.
ARKG is down about 7% to date.
However, in the past 12 months, the ETF is up about 160%. The company’s flagship fund is the Ark Innovation ETF (ARKK), which is down about 1.6% so far in 2021. ARKK is also up nearly 160% in the past 12 months.